Efficacy and Immune Modulation of the Tumor Microenvironment With the Combination of the PARP Inhibitor Rucaparib and CD122-biased Agonist NKTR-214.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2018.36.15_suppl.5582
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Bempegaldesleukin (NKTR-214): A CD-122-biased IL-2 Receptor Agonist for Cancer Immunotherapy

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2019English

Nanoparticle Modulation of the Tumor Microenvironment Enhances Therapeutic Efficacy of Cisplatin

Journal of Controlled Release
Pharmaceutical Science
2015English

Chemokine Modulation of the Tumor Microenvironment

Pigment Cell and Melanoma Research
BiochemistryDermatologyOncologyGeneticsMolecular Biology
2010English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer
Oncology
2020English

Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

Clinical Cancer Research
Cancer ResearchOncology
2019English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

Multiplexed Imaging Characterizes the Tumor–Immune Microenvironment

Cancer Discovery
Oncology
2018English

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune Checkpoint Blockade

Clinical Cancer Research
Cancer ResearchOncology
2018English

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

Frontiers in Immunology
AllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy